Sanofi explores combination treatments for multiple myeloma in new late-stage trials

Sanofi has launched two new late-stage clinical studies to determine if an investigational biologic called isatuximab, when used in combination with other commonly used cancer treatments, might be an effective treatment option for certain people with multiple myeloma, a rare blood cancer related to lymphoma and leukemia.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news